INBXHealthcare · BiotechnologyThe 3 Wall Street analysts covering Inhibrx Biosciences, Inc. hold a median 12-month price target of $278 — +167.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 26 of 100 as at 22 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Inhibrx Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (91): The shares have been drifting up relative to others.
Quality (8): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on INBX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +167.8% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 8 Apr 2026 | Stifel | Initiates | Buy | $150 |
| 8 Apr 2026 | Stifel | Initiates | Buy | — |
| 22 Aug 2025 | JMP Securities | Reiterates | Market Perform | — |
| 15 May 2025 | JMP Securities | Reiterates | Market Perform | — |
| 18 Mar 2025 | Citizens Capital Markets | Reiterates | Market Perform | — |
| 22 Jan 2025 | JMP Securities | Reiterates | Market Perform | — |
| 23 July 2024 | JMP Securities | Initiates | Market Perform | — |
| 23 Jan 2024 | JMP Securities | Downgrade | Market Perform | — |
| 20 Nov 2023 | JMP Securities | Reiterates | Market Outperform | — |
| 23 Aug 2023 | JMP Securities | Maintains | Outperform | — |
| 10 May 2023 | JMP Securities | Reiterates | Market Outperform | — |
| 8 Mar 2023 | JMP Securities | Maintains | Market Outperform | — |
| 7 Mar 2023 | Credit Suisse | Reiterates | Outperform | — |
| 8 Nov 2022 | Credit Suisse | Maintains | Outperform | — |
| 5 Oct 2022 | Evercore ISI Group | Maintains | Outperform | — |
| 25 Aug 2022 | SMBC Nikko | Initiates | Outperform | — |
| 9 Aug 2022 | Credit Suisse | Maintains | Outperform | — |
| 16 Mar 2022 | SMBC Nikko | Initiates | Outperform | — |
| 2 Mar 2022 | JMP Securities | Maintains | Market Outperform | — |
| 10 Nov 2021 | Credit Suisse | Maintains | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. INBX appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 72% of US stocks
Cheaper than 1% of US stocks
Cheaper than 99% of US stocks
Cheaper than 85% of US stocks
Higher than 2% of US stocks
Higher than 30% of US stocks
Higher than 1% of US stocks
Higher than 9% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Inhibrx Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Inhibrx Biosciences reported its financial results for the second quarter of 2026, noting that it has two programs in ongoing clinical trials.
Why it matters — The update provides a routine financial and operational checkpoint for a biopharmaceutical company with active clinical-stage programs.
The 3 Wall Street analysts covering Inhibrx Biosciences, Inc. have a median 12-month price target of $278, with estimates ranging from $230 to $325. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 3 analysts covering Inhibrx Biosciences, Inc., 2 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Inhibrx Biosciences, Inc. 26 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, Inhibrx Biosciences, Inc. ranks 26 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (91 of 100).
No one can know that. What the data says: the median 12-month target from 3 analysts implies +167.8% from the last close, and Ticker Nerd's factor model ranks Inhibrx Biosciences, Inc. 26 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Inhibrx Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for INBX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $230 to $325 over the next 12 months.
Inhibrx Biosciences, Inc. returned +328.9% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Inhibrx Inc. is a biotechnology company that focuses on developing monoclonal antibodies used for treating a range of life-threatening diseases.
The most recent item we track (PRNewsWire, 13 Aug 2026): "Inhibrx Reports Second Quarter 2026 Financial Results". Inhibrx Biosciences reported its financial results for the second quarter of 2026, noting that it has two programs in ongoing clinical trials.
Inhibrx Inc. is a biotechnology company that focuses on developing monoclonal antibodies used for treating a range of life-threatening diseases. The company’s primary objective is to innovate targeted therapies that can address significant unmet medical needs in the areas of oncology, rare diseases, and autoimmune conditions. Notably, Inhibrx leverages its proprietary single-domain antibody technology platform to engineer highly differentiated biological therapies. By concentrating on precision medicine, the firm's approach aims to deliver more effective solutions with the potential for enhanced patient outcomes as compared to traditional treatments. Operating in the burgeoning biotechnology sector, Inhibrx contributes to the advancement of medical research and the development of targeted therapies. The company's role in the financial market encompasses that of a high-growth potential entity, attracting interest from investors focused on cutting-edge healthcare innovations and the broader biotechnology industry developments.
CEO Mr. Mark Paul Lappe · 109 employees · United States · https://inhibrx.com